Oxprofen™ – Next-Generation Ibuprofen
Oxprofen is an aluminium–magnesium LDH salt of ibuprofen delivering faster onset while maintaining ibuprofen’s proven safety.
Clinical Evidence
• Bioequivalence for AUC and Cmax
• Tmax ≈30 min – 25–35% faster than ibuprofen lysine (Tmax ≈40–45 min) in head-to-head comparison
• Intrinsic taste-masking
• Early endoscopy data indicate improved gastric comfort relative to standard formulations
Market Applications
• OTC: Fast-acting, taste-masked ibuprofen for everyday pain relief
• Rx: Acute and emergency care requiring rapid onset; suitable for replacing diclofenac in higher-dose applications
Regulatory Pathway
Eligible for 505(b)(2) (US) or 10(3) hybrid (EU), with the option for direct OTC registration depending on jurisdiction.
Development Status
Phase 1 PK complete; FDA and EMA guidance supports streamlined pathways.
Pipeline Extensions
Building on Oxprofen’s pharmacokinetic and safety profile, Oxford PharmaScience is advancing LDH naproxen as a complementary fast-acting OTC analgesic for sustained pain relief. In the prescription setting, Oxprofen itself provides a fast-onset alternative to diclofenac, addressing the unmet need for a safe, rapid-acting NSAID suitable for acute pain, migraine, and post-procedural use.
Intellectual Property – Patents granted and pending across major markets.
Contact: contact@pharmascience.co.uk